Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma

H. Asaoku, M. Kawano, K. Iwato, O. Tanabe, H. Tanaka, T. Hirano, T. Kishimoto, A. Kuramoto

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Human myeloma cells freshly isolated from 40 patients with IgG multiple myeloma (MM, 10 in stage I and 30 in stage III), were cultured for 48 hours with recombinant B cell stimulatory factor 2 (rBSF-2)/interleukin-6 (IL-6), which is considered a major growth factor for myeloma cells. Uptake of 3H-thymidine by these purified myeloma cells was measured, and BSF-2 response was evaluated by stimulation index and Δcpm induced by rBSF-2. Myeloma cells from cases in stage I responded to rBSF-2 better than those in stage III. Moreover rBSF-2 responders also showed better response to chemotherapy. Therefore, these results suggest that in vitro response of myeloma cells to BSF-2 correlates with disease progression and clinical response in patients of MM.

Original languageEnglish
Pages (from-to)429-432
Number of pages4
Issue number2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma'. Together they form a unique fingerprint.

Cite this